B

Brown University Health

Remote behavioral health care platform analytics

Clinical Pharmacist - Oncology Sterile Compounding

Part-Time
$110.3k - $182k
Mid
Bachelor's, MD
Providence, RI, USA
In PersonOccasional travel between facilities or sites may be required.
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • A Bachelor of Science in Pharmacy or Doctor of Pharmacy degree from an accredited college of pharmacy is required.
  • Before the start date, the candidate must hold current unrestricted licensure as a licensed pharmacist or licensed 90-day temporary pharmacist in Rhode Island; full licensure must be obtained before the temporary license expires and maintained thereafter.
  • Effective written and verbal interpersonal and communication skills to interact appropriately with patients, families, colleagues, and others are required.
  • Effective organizational and presentation skills are required.
  • Knowledge of specialty-specific technology, including pharmacy information systems, automated dispensing technology, software, equipment, and automation, is required.
  • Experience with Microsoft Word, Excel, Outlook, and web browsers is required.
  • The candidate must be able to multitask and reprioritize while maintaining accuracy and service standards.
  • Within two months of hire, the candidate must obtain and maintain internal IV and oncology credentialing, demonstrated by successful completion of current competency assessments at least semi-annually.
  • The role requires extended periods of standing and walking and the visual and manual dexterity to operate a computer.
Responsibilities
  • Interpret, evaluate, prepare, and dispense medications pursuant to legitimate orders and established policies, procedures, standards of practice, and the scope of pharmacy services for inpatient and outpatient oncology, hematology, and other patients.
  • Collaborate with and serve as a liaison and resource for the interdisciplinary team managing patients at Rhode Island Hospital, Hasbro Children’s Hospital, and affiliate clinics.
  • Maintain working knowledge of compounding and sterile-preparation principles, stability, and compatibility.
  • Maintain working knowledge of and perform non-sterile compounding in compliance with applicable United States Pharmacopeia standards, National Institute for Occupational Safety and Health recommendations, and organizational policies and procedures.
  • Maintain compliance with regulatory boards and regulations related to sterile pharmaceutical compounding, including Rhode Island requirements, United States Pharmacopeia standards, National Institute for Occupational Safety and Health recommendations, and The Joint Commission Medication Management chapter.
  • Review, monitor, and verify oral and parenteral chemotherapy and other medication orders for drug, dosage, route, completeness, and potential incompatibilities.
  • Verify chemotherapy and adjuvant medication orders against therapy plans, treatment plans, protocols, standards of care, and pediatric roadmaps; identify, recommend, communicate, and clarify appropriate therapy changes or unclear orders with prescribers.
  • Ensure clinical pharmacy services and programs meet established standards of care and patient-care quality standards while accounting for patient developmental stages from neonatal through geriatric populations.
  • Follow procedures for dispensing chemotherapy agents when prescribed doses exceed defined daily or regimen ceilings and comply with maximum-dose warnings.
  • Reference investigational drug protocols and follow procedures for preparing, dispensing, and documenting investigational drugs.
  • Perform computer activities necessary for compounding, follow product documentation and check-process requirements, and accurately document finished compounded medications.
  • Perform detailed in-process medication checks for the drug, diluent, volumes, base solution, beyond-use date, storage requirements, and labeling.
  • Maintain knowledge of safe handling, administration, and disposal of hazardous drugs; provide guidance for effective treatment of extravasations; access safety data sheets and respond appropriately to hazardous medication exposures or spills.
  • Provide input on safety events related to oncology and sterile-compounding services to reduce recurrence risk.
  • Use health-literacy skills to counsel patients effectively on treatment regimens, precautions, and adverse reactions to monitor.
  • Provide oversight of daily oncology and compounded sterile-product operations, including the aseptic processing environment, garbing, aseptic work practices, and cleaning and disinfection procedures.
  • Provide oversight to and mentor oncology and sterile-compounding technicians, residents, and students.
  • Participate in orientation and training for pharmacists, residents, student interns, technicians, and student externs.
  • Use LifeChart reporting and inventory-management systems effectively and collaborate with oncology pharmacy and purchasing teams to procure medications and supplies in a timely manner.
  • Set up, calibrate, and operate ancillary compounding equipment, including pumps.
  • Follow downtime procedures.
  • Provide input on policies and procedures for oncology and sterile-compounding services.
  • Participate in continuous quality-improvement initiatives for oncology and sterile-compounding services.
  • Maintain professional competence through staff-development and skills-enhancement programs, independent study, and participation in professional organizations.
  • Proactively address issues affecting pharmacy oncology services.
  • Perform duties of other pharmacist job categories as required.
  • Refer specific complex problems to a supervisor when departmental policies or procedures require clarification.
  • Travel between facilities or sites occasionally as required.
Desired Qualifications
  • Successful completion of an accredited Post Graduate Year 1 residency and/or national Board Certification in Pharmacotherapy is preferred.
  • Successful completion of an accredited Post Graduate Year 2 residency in the area of specialty is strongly preferred, if applicable.
  • Clinical experience, knowledge, and development may be considered in lieu of formal training.

About the company

B

Brown University Health

View

Memoir Health provides a behavioral healthcare platform that enables home-based care for behavioral health and substance use issues. It helps health systems remotely manage patients with tools like remote patient monitoring, scheduling, virtual care, and outcomes management, powered by a data analytics engine that highlights cost-saving opportunities and supports automated workflows and one-click referrals. The platform differentiates itself by automating care journeys and delivering integrated, outcomes-focused care within managed care and other healthcare networks, reducing administrative workload for clinicians. Its goal is to make care more proactive, accessible, and coordinated from patients’ homes, improving outcomes while lowering costs, and Memoir Health was later acquired by Lumeo Health in 2020.

Company Size

1-10

Company Stage

Seed

Total Funding

$7.5M

Headquarters

New York City, New York

Founded

2018

Get referred to Brown University Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A $37 million Starr Foundation alliance launched September 2026 for aging research.
  • Brown Health targets 30,000 new primary-care patients and 27 hires over three years.
  • Primary-care waitlists fell from 14,000 to 4,800, showing access improvements.

What critics are saying

  • UnitedHealthcare Medicare Advantage cutoffs hit 1,900 members in July 2026, hurting referrals.
  • A Massachusetts data breach investigation remains unresolved, exposing patient trust and regulatory risk.
  • Fiscal 2025 margin was 0.9%; weak reimbursement can trigger another existential liquidity squeeze.

What makes Brown University Health unique

  • Brown University Health unites Lifespan hospitals with Brown University academic medicine since 2025.
  • Its 2025 Brown Physicians merger added 500-plus physicians and 1,500-plus providers.
  • Epic, Workday, and Brown-aligned research integration create a larger operating platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Paid Sick Leave
  • Productivity Bonus
  • Stock Options
  • Company Equity

Company News

Providence Business News
Apr 25th, 2023
Miriam Hospital’s palliative care program is first in R.I. and one of few in U.S.

LIFESPAN CORP. and HopeHealth launched the state’s first palliative care program in the emergency department of The Miriam Hospital.

Providence Business News
Jan 4th, 2023
Markell named New CFO of Lifespan Corp.

PETER K. MARKELL was named Lifespan Corp. ’s new chief financial officer and executive vice president, starting Jan. 30.

Providence Business News
Dec 26th, 2022
Pareek appointed chief of urology for Lifespan hospitals

PROVIDENCE – Lifespan Corp. has appointed Dr. Gyan Pareek as chief of urology in the department of surgery at Lifespan hospitals and president of Brown Urology Inc.

Providence Business News
Dec 15th, 2022
Lifespan Cancer Institute launches career program for young people of color

PROVIDENCE – The Lifespan Cancer Institute is launching a new program to train high school students of color for a career in cancer research and medicine.

Business Wire
Dec 15th, 2022
Trisalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (Perio™) Clinical Trial Progress And Pre-Clinical Research Developments

DENVER & CHICAGO--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or “MTAC”), today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional Immuno-Oncology™ (“PERIO™-01” and “PERIO™-02”) clinical program.In recent months TriSalus has opened five new PERIO™-01 (NCT04935229) clinical trial sites, at Stanford University Hospitals, University of California Los Angeles, University of Colorado’s Anschutz Medical Campus, University of Washington Medical Center and University of Miami’s Sylvester Comprehensive Cancer Center, in addition to five previously activated sites. The PERIO™-01 trial is studying an investigational drug, SD-101, delivered intravascularly by the TriNav® Infusion System (“TriNav®”) using the company’s proprietary Pressure-Enabled Drug Delivery™ (“PEDD™”) method of administration. The study is evaluating whether this platform approach with SD-101 and PEDD™ can improve the performance of systemic checkpoint inhibitors in treating patients with uveal melanoma with liver metastases. In addition to these U.S. sites, TriSalus anticipates opening future PERIO™-01 clinical trial sites in the United Kingdom, Europe, and Canada.In parallel, TriSalus opened PERIO™-02 (NCT05220722) trial sites at Columbia University and University of Colorado Denver, along with Rhode Island Hospital – which was announced last month as part of an expanded research collaboration with Lifespan Health System